Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406926 · ClinicalTrials.gov registry record · Phase 3
The Effect of Growth Hormone in Very Young Girls With Turner Syndrome
A Phase 3 study of Turner Syndrome, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 10
- Study locations
NCT00406926: Completed Phase 3 study of Turner Syndrome, sponsored by Eli Lilly and Company.
NCT00406926 is a Phase 3 study of Turner Syndrome that has completed, run by Eli Lilly and Company. The registered enrollment target is 100 participants, below the 512-participant average among 14 other Turner Syndrome trials with a reported enrollment target (80% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00406926, a Phase 3 study of Turner Syndrome, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study investigated the effect of growth hormone on the growth of infants and toddlers with Turner syndrome during 2 years of treatment with growth hormone. This was compared with the growth of infants and toddlers with Turner syndrome who did not receive any growth hormone treatment. The overall aim was to prevent the growth failure usually seen during this period. The study also looked at middle ear disease, hearing problems, and cognitive and behavioral development.
Conditions Studied
Interventions
- DRUG Somatropin
Study Locations (10)
California
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Los Angeles
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Stanford
Colorado
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Denver
Connecticut
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Hartford
Illinois
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Chicago
Indiana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Indianapolis
Kentucky
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Lexington
Missouri
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kansas City
Pennsylvania
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 1999-08 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
What the finished NCT00406926 record still lists
NCT00406926 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 512-participant average among 14 other Turner Syndrome trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Turner Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Somatropin is the first listed.
NCT00406926 lists 10 locations in 9 states (California, Colorado, Connecticut).
Frequently Asked Questions
What is clinical trial NCT00406926 about?
NCT00406926 is a clinical study titled "The Effect of Growth Hormone in Very Young Girls With Turner Syndrome". This study investigated the effect of growth hormone on the growth of infants and toddlers with Turner syndrome during 2 years of treatment with growth hormone. This was compared with the growth of infants and toddlers with Turner syndrome who did not receive any growth hormone treatment. The overal...
What is the current status of trial NCT00406926?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 1999-08. Estimated completion is 2003-08.
What conditions does trial NCT00406926 study?
This clinical trial studies the following conditions: Turner Syndrome.
What interventions are being tested in trial NCT00406926?
The interventions under investigation include: Somatropin (DRUG).
Who is sponsoring clinical trial NCT00406926?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406926 being conducted?
This trial has 10 study locations across California, Colorado, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Turner Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00406926's enrollment target sits among peer trials
100 8th of 14 higher than 7 of 14 other Turner Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Turner Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
RECRUITING · Phase 3
-
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
ACTIVE NOT RECRUITING · Phase 3
-
Natural History of Noncirrhotic Portal Hypertension
RECRUITING
-
UTHealth Turner Syndrome Research Registry
RECRUITING
-
Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
RECRUITING · Phase 4
-
Vosoritide for Short Stature in Turner Syndrome
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia